Prophylactic/therapeutic agent for dry eye

Abstract

This invention provides a prophylactic and therapeutic agent for dry eye, having new ingredients to reduce the deterioration of the lacrimal secretory ability and to inhibit the generation of radical oxygen in lacrimal gland tissue. The prophylactic and therapeutic agent for dry eye of this invention contains the maqui berry extract as the active substance of this invention, i.e. containing delphinidin glycoside extracted from the maqui berry and at least one or more of the active substances delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, preferably delphinidin-3,5-diglucoside.

1 - 3 . (canceled) 
     
     
         4 . Prophylactic and therapeutic agent for dry eye, containing delphinidin-3,5-diglucoside as an active substance. 
     
     
         5 . Prophylactic and therapeutic agent for dry eye, comprising maqui berry extract including containing delphinidin-3,5-diglucocide. 
     
     
         6 - 7 . (canceled) 
     
     
         8 . Inhibitor to the deterioration of the lacrimal secretory ability, comprising delphinidin-3,5-diglucoside, as an active substance. 
     
     
         9 . Inhibitor to the deterioration of the lacrimal secretory ability, comprising the maqui berry extract, including containing delphinidin-3,5-diglucocide. 
     
     
         10 - 12 . (canceled) 
     
     
         13 . Inhibitor to the generation of radical oxygen in the lacrimal gland tissue, containing delphinidin-3,5-diglucoside as an active substance. 
     
     
         14 . Inhibitor to the generation of radical oxygen in the lacrimal gland tissue, comprising the maqui berry extract containing delphinidin-3,5-diglucocide as an active substance. 
     
     
         15 . A method for manufacturing the prophylactic and therapeutic agent for dry eye, comprising step (a) to obtain extract liquid from the maqui berry fruit, (b) to filter the liquid obtained in the above step (a) and pass it through a synthetic-absorbent column chromatography, (c) to obtain an extracted liquid by hydrous ethanol in the synthetic-absorbent column chromatography used in the above step (b), and (d) to prepare the prophylactic and therapeutic agent for dry eye from the maqui berry extract obtained by drying the extracted liquid of the above step (c).